Atsuya Yamashita
Overview
Explore the profile of Atsuya Yamashita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
462
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamashita A, Kasai H, Maekawa S, Tanaka T, Akaike Y, Ryo A, et al.
Antiviral Res
. 2024 Nov;
232:106027.
PMID: 39489302
The current antiviral agents for the treatment of chronic infection with hepatitis B virus (HBV) do not completely remove covalently closed circular DNA (cccDNA) and integrated viral DNA fragments from...
2.
Kasai H, Yamashita A, Akaike Y, Tanaka T, Matsuura Y, Moriishi K
mBio
. 2024 Sep;
15(11):e0169124.
PMID: 39329491
We previously reported that hepatitis C virus (HCV) infection or HCV core protein expression induces HOX gene expression by impairing histone H2A monoubiquitination via a proteasome-dependent reduction in the level...
3.
Toyama M, Watashi K, Ikeda M, Yamashita A, Okamoto M, Moriishi K, et al.
Antimicrob Agents Chemother
. 2022 May;
66(6):e0207321.
PMID: 35604213
Novel neplanocin A derivatives have been identified as potent and selective inhibitors of hepatitis B virus (HBV) replication . These include (1S,2R,5R)-5-(5-bromo-4-methyl-7H-pyrrolo[2,3-d]-pyrimidin-7-yl)-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol (AR-II-04-26) and (1S,2R,5R)-5-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)-3-(hydroxylmethyl)cyclopent-3-ene-1,2-diol (MK-III-02-03). The 50% effective concentrations...
4.
Tanaka T, Okuyama-Dobashi K, Motohashi R, Yokoe H, Takahashi K, Wiriyasermkul P, et al.
Antiviral Res
. 2021 Aug;
194:105165.
PMID: 34419484
The development of novel antivirals to treat hepatitis B virus (HBV) infection is still needed because currently available drugs do not completely eradicate chronic HBV in some patients. Recently, troglitazone...
5.
Otoguro T, Tanaka T, Kasai H, Kobayashi N, Yamashita A, Fukuhara T, et al.
Hepatol Commun
. 2021 Apr;
5(4):634-649.
PMID: 33860122
Compared with each monoinfection, coinfection with hepatitis B virus (HBV) and hepatitis C virus (HCV) is well known to increase the risks of developing liver cirrhosis and hepatocellular carcinoma. However,...
6.
Kasai H, Mochizuki K, Tanaka T, Yamashita A, Matsuura Y, Moriishi K
J Virol
. 2020 Dec;
95(6).
PMID: 33328315
Hepatitis C virus (HCV) infection causes liver pathologies, including hepatocellular carcinoma (HCC). Homeobox (HOX) gene products regulate embryonic development and are associated with tumorigenesis, although the regulation of HOX genes...
7.
Matsuda S, Maekawa S, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, et al.
Hepatol Res
. 2020 Sep;
51(1):39-50.
PMID: 32961003
Aim: Recently, serum hepatitis B virus (HBV)-RNA has been reported to be detectable even when HBV particle production is inhibited by nucleot(s)ide analogues (NAs). However, the dynamics of the HBV-RNA...
8.
Muraoka M, Maekawa S, Suzuki Y, Sato M, Tatsumi A, Matsuda S, et al.
Hepatol Res
. 2020 Jun;
50(9):1071-1082.
PMID: 32510681
Aim: The landscape of cancer-related genetic aberrations in hepatocellular carcinoma (HCC) has gradually become clear through recent next-generation sequencing studies. However, it remains unclear how genetic aberrations correlate with imaging...
9.
HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers
Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, et al.
PLoS One
. 2019 Feb;
14(2):e0212559.
PMID: 30794632
Aim: Deletions are observed frequently in the preS1/S2 region of hepatitis B virus (HBV) genome, in association with liver disease advancement. However, the most significant preS1/S2 region and its influences...
10.
Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, et al.
Hepatol Res
. 2018 Oct;
49(1):51-63.
PMID: 30350374
Aim: Although the viral markers hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HbcrAg) could reflect intrahepatic hepatitis B virus (HBV) replication activity and constitute important biomarkers for...